Profile data is unavailable for this security.
About the company
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
- Revenue in USD (TTM)10.63m
- Net income in USD-73.50m
- Incorporated2008
- Employees17.00
- LocationCarisma Therapeutics Inc245 1st St Ste 1800CAMBRIDGE 02142-1292United StatesUSA
- Phone+1 (617) 444-8550
- Fax+1 (617) 858-0911
- Websitehttps://sesenbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RetinalGenix Technologies Inc | 0.00 | -2.09m | 62.25m | 0.00 | -- | -- | -- | -- | -0.1205 | -0.1205 | 0.00 | -0.0797 | 0.00 | -- | -- | -- | -929,284.40 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -543.50 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
Calcimedica Inc | 0.00 | -34.36m | 64.44m | 14.00 | -- | 4.19 | -- | -- | -26.09 | -26.09 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -132.51 | -63.99 | -155.72 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
Mural Oncology PLC | 0.00 | -207.45m | 64.64m | 117.00 | -- | 0.2417 | -- | -- | -12.43 | -12.43 | 0.00 | 15.81 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
Bioqual Inc | 62.86m | 957.02k | 64.85m | 108.00 | 67.76 | 1.67 | 18.49 | 1.03 | 1.07 | 1.07 | 70.28 | 43.41 | 1.04 | -- | 2.99 | -- | 1.59 | 8.14 | 1.80 | 9.52 | 14.13 | 19.36 | 1.52 | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
Maia Biotechnology Inc | 0.00 | -19.77m | 65.86m | 13.00 | -- | 112.05 | -- | -- | -1.49 | -1.49 | 0.00 | 0.0281 | 0.00 | -- | -- | 0.00 | -201.88 | -- | -347.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.91 | -- | -- | -- |
Aligos Therapeutics Inc | 15.53m | -87.68m | 66.08m | 66.00 | -- | 0.6952 | -- | 4.26 | -1.82 | -1.82 | 0.3204 | 1.22 | 0.1041 | -- | -- | 235,287.90 | -58.80 | -51.20 | -72.71 | -59.73 | -- | -- | -564.61 | -1,399.21 | -- | -- | 0.0026 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
Champions Oncology Inc | 49.22m | -9.73m | 66.19m | 230.00 | -- | -- | -- | 1.34 | -0.7183 | -0.7183 | 3.64 | -0.1514 | 1.56 | -- | 6.17 | 214,017.40 | -30.91 | -5.40 | -96.45 | -11.88 | 40.09 | 47.96 | -19.76 | -3.09 | -- | -- | -- | -- | 9.69 | 21.63 | -1,073.54 | -- | 18.50 | -- |
Carisma Therapeutics Inc | 10.63m | -73.50m | 66.47m | 17.00 | -- | 1.39 | -- | 6.25 | -3.70 | -3.70 | 0.411 | 1.15 | 0.0694 | -- | -- | 625,294.10 | -47.96 | -25.47 | -56.78 | -27.87 | -- | -- | -691.39 | -236.32 | -- | -- | 0.0211 | -- | 50.69 | 148.16 | -5,817.86 | -- | -- | -- |
SCYNEXIS Inc | 140.14m | 67.04m | 67.25m | 29.00 | 1.38 | 0.9077 | -- | 0.4799 | 1.29 | 1.29 | 2.90 | 1.96 | 1.30 | 34.76 | 133.41 | 4,832,483.00 | 62.01 | -30.02 | 73.55 | -36.35 | 88.85 | -- | 47.84 | -86.76 | 6.26 | 33.49 | 0.1428 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
enVVeno Medical Corp | 0.00 | -23.52m | 67.38m | 31.00 | -- | 1.46 | -- | -- | -1.96 | -1.96 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -52.09 | -58.43 | -53.82 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
Medicinova Inc | 1.00m | -8.57m | 67.68m | 13.00 | -- | 1.09 | -- | 67.68 | -0.1748 | -0.1748 | 0.0204 | 1.27 | 0.0142 | -- | -- | 76,923.08 | -12.21 | -15.36 | -12.80 | -15.90 | -- | -- | -857.15 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
Celularity Inc | 14.79m | -181.41m | 67.96m | 225.00 | -- | 2.00 | -- | 4.60 | -10.51 | -10.51 | 0.8376 | 1.56 | 0.0498 | 2.29 | 2.03 | 65,724.45 | -61.05 | -- | -82.37 | -- | 21.19 | -- | -1,226.72 | -- | 0.1366 | 18.40 | 0.5365 | -- | -15.75 | -- | 114.18 | -- | -- | -- |
Elutia Inc | 24.75m | -41.25m | 68.18m | 54.00 | -- | -- | -- | 2.76 | -2.20 | -2.08 | 1.35 | -1.66 | 0.4408 | 1.97 | 4.90 | 458,240.80 | -73.48 | -42.93 | -309.94 | -79.34 | 44.67 | 43.32 | -166.70 | -64.16 | 0.6367 | -3.54 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
Rallybio Corp | 0.00 | -74.56m | 69.20m | 43.00 | -- | 0.652 | -- | -- | -1.84 | -1.84 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -50.37 | -- | -54.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
Landos Biopharma Inc | 0.00 | -21.94m | 69.55m | 19.00 | -- | 2.18 | -- | -- | -3.49 | -3.49 | 0.00 | 10.20 | 0.00 | -- | -- | 0.00 | -52.67 | -59.84 | -61.86 | -72.15 | -- | -- | -- | -795.80 | -- | -516.52 | 0.00 | -- | -- | -- | 44.15 | -- | -- | -- |
Assembly Biosciences Inc | 7.16m | -61.23m | 70.23m | 65.00 | -- | 1.71 | -- | 9.81 | -14.02 | -14.02 | 1.63 | 7.50 | 0.06 | -- | 14.51 | 110,200.00 | -51.32 | -39.69 | -66.88 | -44.03 | -- | -- | -854.78 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Dec 2023 | 1.72m | 4.27% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 1.55m | 3.84% |
University of Pennsylvania (Investment)as of 31 Dec 2023 | 1.25m | 3.10% |
Geode Capital Management LLCas of 31 Dec 2023 | 515.89k | 1.28% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 500.31k | 1.24% |
Bridgeway Capital Management LLCas of 31 Dec 2023 | 311.03k | 0.77% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 227.05k | 0.56% |
Renaissance Technologies LLCas of 31 Dec 2023 | 213.03k | 0.53% |
Teachers Advisors LLCas of 31 Dec 2023 | 86.47k | 0.21% |
BlackRock Investment Management LLCas of 31 Dec 2023 | 78.39k | 0.19% |